Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trialDebu Tripathy, Yen‐Shen Lu, Seock‐Ah Im et al.|The Lancet Oncology|2018Cited by 1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Joseph Gligorov et al.|Annals of Oncology|2021Cited by 724
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtypeLorenzo Gerratana, Grazia Arpino, Debora Basile et al.|Cancer Treatment Reviews|2018Cited by 282
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatmentMario Giuliano, Massimo Cristofanilli, Vicente Valero et al.|Breast Cancer Research|2011Cited by 224
CDK 4/6 Inhibitors as Single Agent in Advanced Solid TumorsFrancesco Schettini, Lucia Del Mastro, Irene De Santo et al.|Frontiers in Oncology|2018Cited by 205